FDA Releases Guidelines On Cannabis Research Following White House Review

The Food and Drug Administration (FDA) published draft guidance on developing cannabis-based drugs on Tuesday.

This comes weeks after the White House completed its review of the document, clearing its path for public release.

FDA is still in the process of developing regulations that could allow for CBD to be marketed as a food item or dietary supplement, but in the meantime it has worked to create these new research guidelines for drug manufacturing.

Much of the guidance—which is “limited to the development of human drugs and does not cover other FDA-regulated products”—covers the basics of conducting federally authorized research for drug development purposes such as where researchers are allowed to obtain cannabis and the importance of demonstrating the ability to “consistently manufacture a quality product.”